Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Philippe L. Bedard, Michael A. Davies, Scott Kopetz, Keith T. Flaherty, Geoffrey Shapiro, Jason John Luke, Anna Spreafico, Bin Wu, Corinne Gomez, Sylvaine Cartot-Cotton, Florent Mazuir, Sandrine Micallef, Brigitte Demers, Dejan Juric | ||||||||||||
Title | First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737). | ||||||||||||
|
|||||||||||||
URL | http://meetinglibrary.asco.org/content/146302-156 | ||||||||||||
Abstract Text | J Clin Oncol 33, 2015 (suppl; abstr 2564) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN loss | Advanced Solid Tumor | no benefit | SAR260301 | Phase I | Actionable | In a Phase I trial, SAR260301 demonstrated acceptable safety but undesirable pharmacokinetics, and resulted in no response in patients with advanced solid tumors harboring PTEN loss (J Clin Oncol 33, 2015 (suppl; abstr 2564)). | detail... |